Marker Therapeutics, Inc. — Director's Dealing 2018

Sep 25, 2018

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: TAPIMMUNE INC. (TPIV)
CIK: 0001094038
Period of Report: 2018-09-22

Reporting Person: WILSON GLYNN (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2018-09-22	Common Stock	$	A	31120	Acquired		Common Stock (31120)	Direct

Footnotes

F1: Represents the number of shares of restricted stock the reporting person has a present right to receive under the terms of the amendment to his employment agreement with the Company, and such shares are based on a value of $300,000 and the closing price of the Company's common stock on September 21, 2018 of $9.64 per share, (which was the date immediately preceding the anniversary of the amendment) and upon issuance under the Company's 2014 Omnibus Stock Ownership Plan to be fully vested.